A PYMNTS Company

US: Judge demands settlement documents from Boehringer

By  |  September 29, 2016

A federal judge has ordered Boehringer Ingelheim Pharmaceuticals Inc to turn over several documents related to settlements it reached with generic rival Barr Laboratories to the Federal Trade Commission, finding they are not protected as work product prepared in anticipation of litigation.

The FTC is looking into whether the 2008 settlements, which resolved patent claims asserted by Boehringer against Barr over its anti-clotting drug Aggrenox and Parkinson’s drug Mirapex, involved illegal payments to Barr to delay generic versions.

Full Content: Reuters

Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.